Tests NA-931 with or without tirzepatide in adults with obesity or overweight
Tests a pill, NA-931, alone or with tirzepatide in adults who have obesity or overweight.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Key facts
- Where
- Auckland, Hamilton, Newtown, and Papatoetoe, New ZealandSee the 4 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with overweight or obesity who have tried to lose weight on their own without success.
- Age
- 18 to 80 years (the registry header lists 19 to 80 years)
- Sex
- Men and women can join.
- Disease stage
- BMI of 30 or more, or BMI of 27 or more with one or more weight-related health problems such as high blood pressure, insulin resistance, sleep apnea or high blood fats. Body weight under 150 kg (331 lb).
- Earlier treatment
- At least one self-reported unsuccessful effort to lose weight through behaviour change. No medication for obesity in the 30 days before screening.
Main reasons for not taking part
- Known allergy to monoclonal antibody drugs or a reason not to take Tirzepatide
- Diabetes treated with diabetes drugs, or HbA1c of 6.5% (48 mmol/mol) or more
- Chronic infection such as hepatitis B, hepatitis C or HIV, or active COVID-19
- Other investigational drugs within 30 days or 5 half-lives
- Weight change of more than 5 kg (11 lb) in the 90 days before screening
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 80 years old?
Source: NCT06732245, who can take part
Where in New Zealand
- Biomed Research Unit-NZ-1010-114Auckland, New ZealandNo longer taking part
- Hamilton, New Zealand, 3200 Biomed Research Unit-NZ-3200-116Hamilton, New ZealandNo longer taking part
- Biomed Research Unit-NZ- 6242-117Newtown, New ZealandNo longer taking part
- Biomed Research Unit-NZ-2025-115Papatoetoe, New ZealandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Biomed Industries, Inc.
- Trial code
- NCT06732245
- Record updated
- 27 March 2026
- Original description
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and womenRead full original descriptionShow less
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
Inclusion: A written informed consent must be obtained before any study-related assessments are performed; Men and women between 18 and 80 years, inclusive; women of child-bearing potential (defined as those who are not post-menopausal or post-surgical sterilization) must meet both of the following criteria:; Two negative pregnancy tests (at screening and at randomization, prior to dosing); Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of NA-931/placebo oral, and an additional contraceptive (barrier) method from screening through at least 4 months after the last dose of NA-931/placebo oral; Body mass index (BMI) ≥ 30 or BMI ≥ 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia); Stable body weight (± 5 kg) within 90 days of screening, and body weight <150 kg; Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight; Able to communicate well with the Investigator, comply with the study requirements and adhere to the diet and activity programs for the study duration.
Exclusion: • History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to Tirzepatide (Zepbound® or Mounjaro®); Use of other investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations; Treatment with any medication for the indication of obesity within the past 30 days before screening; Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥ 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion; Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection; Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (> 250 mL) within 14 days prior to the first dose; Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol.